Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prothena (PRTA)
NASDAQ:PRTA
PRTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.70 - $33.84
Previous CloseN/A
Volume58.73K
Average Volume (3M)629.97K
Market Cap
$840.49M
Enterprise Value$392.14M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Feb 13, 2025EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.48
Shares Outstanding53,808,730
10 Day Avg. Volume407,409
30 Day Avg. Volume629,973
Standard Deviation0.26
R-Squared0.00040
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.30
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.04
Enterprise Value/Ebitda-2.46
Forecast
1Y Price Target
$50.25Price Target Upside257.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Drug EfficacyDespite not meeting the primary endpoint, the data provides evidence of clinical activity, which supports moving the program forward.
Research DevelopmentsPrasinezumab was well-tolerated with an adverse event profile consistent to previous findings, but the trial did not show statistically significant decreases in motor progression.
Safety ProfileThe drug was found to be safe and tolerable with no new safety signals.
Bears Say
Phase 2 TrialsThe Phase 2b PADOVA study narrowly missed the statistical significance in the primary endpoint of time to confirmed motor progression.
Program UncertaintyThe update creates uncertainty on the future of the program as definitive evidence of clinical benefit is still needed after two failed phase 2 trials.
Regulatory ChallengesThere is a need for 2 large phase 3 trials for registration, which pushes the estimated timelines for the launch of prasinezumab to 2030.
---
Ownership Overview
13.43% Insiders
31.27% Mutual Funds
0.10% Other Institutional Investors
46.24% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $11.70 and its highest was $33.84 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $840.49M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Feb 13, 2025 which is in 2 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Nov 12, 2024. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.168 by $0.068.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -1.02.
How many shares outstanding does Prothena have?
Prothena has 53,808,730 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.168. Following the earnings report the stock price went down -0.749%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in PRTA
---
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.25 (257.65% Upside)
$50.25 (257.65% Upside)
Hedge Fund Trend
Decreased
By 1.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.56%
12-Months-Change
Fundamentals
Return on Equity
-24.67%
Trailing 12-Months
Asset Growth
-20.31%
Trailing 12-Months
Company Description
Prothena
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
---
PRTA Stock 12 Month Forecast
Average Price Target
$50.25
▲(257.65% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Alnylam Pharma
―
Biogen
―
Ionis Pharmaceuticals
―
SAGE Therapeutics
―
Best Analysts Covering PRTA
1 Year
1 Year Success Rate
11/25 ratings generated profit
1 Year Average Return
+74.05%
reiterated a buy rating 5 days ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 44.00% of your transactions generating a profit, with an average return of +74.05% per trade.
---